Evaluation of the efficacy and safety of risperidone in children
https://doi.org/10.25694/URMJ.2018.12.16
Abstract
In modern children's psychiatric practice, atypical antipsychotics, in particular risperidone, are increasingly being used, in connection with good tolerability and efficacy. In the study of patients with schizophrenic disorders at the age of 5 to 15 years who received risperidone, efficacy in the treatment of negative symptoms in 91.6% (n = 11) was observed. At the same time, adverse neuroendocrine effects were found. So, a statistically significant increase in prolactin was noted, the indices of which went beyond the permissible norm after 1 month of treatment and blood glucose, but its level did not exceed the permissible norm. Also, all patients had an increase in body weight and height.
About the Authors
E. V. Malinina
ФГБОУ ВО ЮУГМУ Минздрава России
Russian Federation
Russian Federation
I. V. Zabozlaeva
ФГБОУ ВО ЮУГМУ Минздрава России
Russian Federation
Russian Federation
T. N. Chizhova
ГБУЗ ОКСПНБ № 1, г. Челябинск
Russian Federation
Russian Federation
O. I. Pilyavskaya
ФГБОУ ВО ЮУГМУ Минздрава России
Russian Federation
Russian Federation
V. V. Kolmogorova
ФГБОУ ВО ЮУГМУ Минздрава России
Russian Federation
Russian Federation
References
1. Алешкина Г.А. Применение атипичных нейролептиков в лечении больных параноидной шизофренией, страдающих сахарным диабетом типа 2: Автореферат диссертации.. на соискание ученой степени кандидата медицинских наук, 2010.
2. Бурназян Г.А. Психофармакотерапия. Айастан, 1985. - 344 С.
3. Горобец Л.Н. Нейроэндокринные дисфункции у больных шизофренией шизоаффективным расстройством в условиях современной антипсихотической терапии (клинико-биохимическое исследование): автореферат диссертации на соискание ученой степени доктора медицинских наук, 2007.
4. Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии: клиника, диагностика, факторы риска и коррекция // Журнал неврологии и психиатрии, 2014. - № 10. -С122-128.
5. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М: Триада, 2004. - 304 р.
6. Дзеранова Л.К., Васюкова О.В., Гончаров Н.П., Гитель Е.П., Колесникова Г.С. , Добрачева А.Д. Макропролактинэмия у подростков с Метаболическим синдромом // Ожирение и метаболизм, 2006. - № 2. - С. 17-20.
7. Малинина Е.В., Забозлаева И.В., Пилявская О.И. и др. / Справочник по психофармакотерапии в детском возрасте, 2016. - С 192.
8. Мосолов С. Н. Современная антипсихотическая терапия шизофрении / «РМЖ», 2004. - № 10. - С 646.
9. Colao A., Loche S., Cappa M. at al. Prolactinomas in children and adolescents. Clinical presentation and long term follow up. / Journal Clinical. Endocrinology and Metabolism 1998. V. - 83. - Р. 2777 - 2780.
10. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 2009. 302- С. 1765-1773.
11. Fideleff H.L., Ruibal G., Boquete H at al. Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res 2000. - V 53. - № 1. - Р.16 - 19.
12. Kumra S, Frazier JA, Jacobsen LK et al. Childhood-onset schizophrenia. A double-blind clozapinehaloperidol comparison. Arch Gen Psychiatry 1996,'53: 1090- 7.
13. Miller delD, CaroffSN, Davis SM et al.: Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 193(4), 279-288 (2008).
14. Offidani E, Fava GA, Tomba E, Baldessarini R.J. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: systematic review. / Psychother Psychoso,, 2013. - Vol. 82. С. 132-141
15. Riordan H.J., Antonini P., MD; Murphy M. F., Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications // American Health & Drug Benefits, 2011. - Vol. 4. - № 5. - Р. 292-301.
16. Varley C.K., McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA. 2009; 302: 1811 -1812
17. Sporn A.L., Vermani A., Greenstein D.K. et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007; 46: 1349-56.
18. Shaw P., Sporn A., Gogtay N. et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison // Arch. Gen. Psychiatry. 2006. Vol. 63, N 7. P. 721-730.
19. http://grls.rosminzdrav.ru/
Review
For citations:
Malinina EV, Zabozlaeva IV, Chizhova TN, Pilyavskaya OI, Kolmogorova VV. Evaluation of the efficacy and safety of risperidone in children. Ural Medical Journal. 2018;(12):27-31. (In Russ.) https://doi.org/10.25694/URMJ.2018.12.16
Views:
133
Email this article 